Business and Finance

Survey shows close interplay between manufacturers and their trading partners for supplemental services

Annual survey rank public companies by environmental, social criteria

Industry woes go beyond current global economic downturn

Annual compilation tracks evolution of wholesaler services, adoption of new technologies

With sales of human pharmaceuticals languishing, several factors are focusing increased attention on animal health products, once a little-noticed industry niche market

Program seeks to improve the economics of care for low-income families; more sites to come

Specific, technology-based anticounterfeiting measures are a tactical response to a strategic problem. Holistic prevention strategies are needed

At 28% pharmaceutical sales, chain pharmacy still represents the single largest channel for delivering prescriptions to patients

Coming off a record-setting year, ABC stresses growth in generics, and services revolving around specialty pharmaceuticals

Effective integration of a company’s contract strategy with operations can have a big impact on financial performance

While drug spending by clients averaged 3.3% last year, higher spending growth is predicted for the next three years

US market will enter negative growth this year, says IMS Health

Specialty manufacturers have a range of options to consider in how to go to market

Better use of available data can add rigor to analyzing managed-markets contracts, thereby allocating rebates / discounts more effectively

US total reaches $291.5 billion; dispensed prescriptions up 0.9%

New unit will ship from La Vergne, TN specialty-care products warehouse

Specialty GPO is doubling attendance year-over-year

US total reaches $291.5 billion; dispensed prescriptions up 0.9%

Although human trials in the U.S. are still a novelty, developers are identifying both sources and protocols for conducting therapy

Although beset by less-than-friendly federal reimbursement policies, independent pharmacies are maintaining their viability for pharmaceutical delivery

Higher complexity—and expense—are the reality for most drug research, says Tufts

Higher co-pays, ‘NDC block policies’ and multiple tiers add to drug benefit complexity

New Deloitte study finds “profound” positive and negative ROIs for combined therapies and diagnostics based on genetics